Vector Innovation Fund Announces Launch of First Advanced Technology Focused Sub-fund for Pandemic Protection
Vector Innovation Fund GP S.à.r.l. (VIF) has now launched an expected $300 million pandemic protection sub-fund 1. This first sub-fund aims to invest in technologies for pandemic protection and future healthcare, aiding and supporting precision medicine, highly advanced point of care and AI technologies to support the global economy, sustainable healthcare, and life longevity. This first sub-fund’s objective is to target commitments totalling $300m due to a strong deal flow, with an expected first close of $120m and a final close expected within 19 months.
The General Partners have an excellent track record in industry, healthcare, technology and investment, with 21 exits and a total value creation of $2.4billion, including two successful IPOs.
VIF is a Reserved Alternative Investment Fund based in Luxembourg has just been incorporated under the laws of the Grand Duchy of Luxembourg as a corporate partnership limited by shares (société en commandite par actions) qualifying as an investment company with variable capital – reserved alternative investment fund (société d’investissement à capital variable – fonds d’investissement alternatif réservé) under the RAIF Law.
VIF has been set up as an umbrella structure with sub-fund Vector Innovation Fund – Pandemic Protection Fund 1 at incorporation date. The General Partner might, at its discretion, launch additional sub-funds (which may be open-ended or close-ended) each of which is represented by one or more Classes of Shares. The fund qualifies as an AIF within the meaning of the AIFM Law.
Each sub-fund shall constitute a distinct and segregated part of the assets and liabilities of VIF’s umbrella structure.
Economic forecasters say fallout from COVID-19 is driving huge investment within AI and Nanotechnology as healthcare investment is expected to grow at a rate of nearly 50% extra a year towards a market set to be worth $1.333 trillion by 2027, according to Precedence Research 2020.
The Pandemic Protection sub-fund 1 plans to invest in sophisticated biotech and nanotechnology-based diagnostics, biomarkers, vaccines, novel therapies, highly targeted nanomedicines, and AI, allowing us to move to a more sustainable, digitised, decentralised and democratised point-of-care environment. The world cannot afford another pandemic, the ongoing impact of long Covid symptoms will have a profound effect on healthcare provision for the next five to ten years. The world of investment, industry and governments are gearing up to be better prepared and are funding future the proof technologies for global health.
These dynamic investments will help to potentially free up our economies and future-proof us from infectious diseases as well as develop solutions to antibiotic resistance, another global healthcare challenge that only technology can solve.
VIF, represented by its managing general partner Vector Innovation GP, has also appointed Fuchs Asset Management S.A., led by CEO Timothe Fuchs. Fuchs Asset Management S.A. is a public limited liability company based in Luxembourg, as the qualified Fund Manager (AIFM) governed under Luxembourg law for reserved alternative investment funds under RAIF Law 2016.
The appointed investment advisor for the fund is Enabling Tech Investment Advisors S.À R.L. who is also based and incorporated in Luxembourg under Luxembourg law. VIF’s depository bank is Banque de Luxembourg. Other international service providers include Maitland, Ashurst, The World Nano Foundation and World Science Aid.
The fund has brought together some of the world’s leading figures in biomedicine, advanced diagnostics, nano biomarkers, telemedicine, AI and machine learning to accelerate these transformational technologies into the markets, backed by sophisticated, UHNW and institutional investors creating potentially one of the most dynamic international investment structures.
VIF’s fund investment strategy looks to deliver 25-30% estimated gross IRR, 4x MOIC over the life of the fund with an estimate of 10-12 diversified investments per sub-fund.
Each prospect company seeking investment from VIF must demonstrate to our investment advisors, our global advisory board, investment committee and fund managers, their ability to commercialise highly disruptive technology globally. For this, VIF uses its unique proprietary rating system for strategy implementation, using world-class benchmark modelling for technology and healthcare investment.
The Fund’s Enabling Technology Investment Advisors and global advisory board are international leaders in these fields of expertise. This has been demonstrated via previous start ups that have gone on to become ‘unicorns’, as well as our team’s wider experience with large conglomerates in terms of advising and supporting them on strategy, scaling or commercialising disruptive innovations in international markets.
One international investment platform is a Pandemic Protection alternative investment fund operated by Vector Innovation Fund in Luxembourg focused on limiting the effect of long form Covid-19, insulating the world against the impact of future pandemics, whilst minimising any impact on the global economy and healthcare provision and preparedness. As well as this, the fund is committed to enhancing the development and prevalence of nanotechnology in healthcare.
The Vector Innovation Fund is a Reserved Alternative Investment Fund (RAIF) specialising in support for technology companies able to transform global markets, notably in global healthcare, sustainability and longevity. These transformational technologies come from the nanotechnology, biotech, AI and machine learning, medical devices, therapies and digital health sectors.
AFP Supports Access to Renewable Energy with €70m
AFP Supports Access to Renewable Energy with €70m
The Agence Francaise de Developpement (AFD) is supporting access to renewable energy for Nigerian manufacturers with €70 million under the Sustainable Use of Natural Resources and Energy Finance (SUNREF) Nigeria Programme for renewable energy.
The fund would be administered through the Access Bank Plc and the United Bank for Africa Plc.
However, only renewable energy projects like solar, wind, small hydro, biomas including waste-to-energy power plants would be eligible for funding under the SUNREF initiative.
The AFP described energy efficiency projects (EEP) as capital expenditure projects that would allow energy consumers to use less energy for achieving the same level of energy service.
The AFP made this known during the Renewable Energy and Energy Efficiency investors’ virtual conference that was held on Wednesday, in partnership with the Nigerian Energy Support Programme (NESP), which is a technical assistance programme co-funded by the European Union (EU) and the German Government and implemented by Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH in collaboration with the Federal Ministry of Power and All-On of the Shell Foundation.
The conference was aimed at enabling the Renewable Energy Association of Nigeria (REAN) to understand the SUNREF’s technical requirements, equipment and installation quality standards, self-regulatory initiatives and certification for industry practitioners.
The President of the Nigerian Manufacturers Association (MAN), Mr. Mansur Ahmed, who participated in the conference, described the financial and technical assistance offered by the SUNREF as significant opportunity that came at a time, “we needed it most more than ever” to address one of the most militating factors against industrial development of Nigeria.
Mansur said: “Clearly, this is the time for every effort to shore up the manufacturing sector is very welcomed. Therefore, I am delighted that this green energy project is focusing on renewable energy in improving energy efficiency.
“It is our hope that our members will take the full advantage of this facility and be able to diversify their energy sources, improve energy consumption and be able to expand their productive capacity, which is indeed very important in the current state of our economy. I, therefore, urge our members to take full advantage of this.”
The Country Director of the AFP, Ms. Virginie Diaz, said in her opening remark during the conference that the SUNREF would basically provide financial and technical assistance “aimed at supporting business strategies in the green energy sector in line with the Paris Agreement on Climate Change, which Nigeria has been supportive of.”
Also, the Head of Cooperation of the EU Delegation to Nigeria and the ECOWAS, Ms. Cecile Tassin-Pelzer, said the conference would enable investors and service providers to showcase their products and be able to develop relationships with clients and prospective investors in Nigeria.
She added: “I will like to highlight that this collaboration is an innovative financing and project that will help to address Nigeria’s energy gaps by mobilising foreign investments to finance green power projects.”
The SUNREF Nigeria Team Lead, Mr. Javier Betancourt, described SUNREF as integrated environmental finance that is dedicated to developing renewable energy in Nigeria.
Betancourt said in his presentation during the conference that the AFD has put in place targeted support to develop innovative green financing through dedicated credit lines through local financial institutions in the country.
He said: “The SUNREF is part of the broader initiative to promote energy efficiency and renewable energy as well as the sustainable use of natural resources.”
According to the Chief Executive Officer of All On, Dr. Wiebe Boer, the mission of the SUNREF is to bring the members of the MAN into the green energy fold.
Boer observed that any opportunity to address the significant gap that exists in access to energy in Nigeria would have considerable economic and social impacts.
Fintech CEO: Morocco’s Move to Revisit CBDC Has Global Implications
Scottsdale, Ari. – February 25, 2021 – Earlier this week, it was reported by both the Morocco World News and NASDAQ that Bank-Al-Maghrib, Morocco’s Central Bank, is forming an exploratory committee to deliberate whether the institution should launch a central bank digital currency. Significantly, only four years ago, the country banned cryptocurrencies.
“It isn’t so significant that yet another country is exploring the benefits of a CBDC, but, rather, the significance is in which country is doing the exploration,” explained Richard Gardner, CEO of Modulus, a US-based developer of ultra-high-performance trading and surveillance technology that powers global equities, derivatives, and digital asset exchanges. “Even the slightest consideration from Bank-Al-Maghrib marks a historic day for digital assets.”
The newly formed committee is said to be tasked with identifying the pros and cons, while remaining cautious due to the “speculative nature” of cryptocurrencies. This is in line with the country’s original critique that a lack of regulation created risk for consumers and investors.
“It’s worth noting that, despite the ban, Moroccans account for the fourth highest volume of trading in Bitcoin within the African continent, behind Kenya, Nigeria, and South Africa,” said Gardner. “A lot has changed in four years. A lot of bureaucrats were leery about the lack of regulatory oversight back then. Even now, many are still cautious. But, the power of cryptocurrencies is real, and they’re here to stay. Especially in Africa, digital currencies could radically change the lives of the unbanked. The fact that Bank-Al-Maghrib is even contemplating the benefits of digital assets — that’s something the whole world will be watching.”
Modulus is known throughout the financial technology segment as a leader in the development of ultra-high frequency trading systems and blockchain technologies. Over the past twenty years, the company has built a client list which includes NASDAQ, Goldman Sachs, Merrill Lynch, JP Morgan Chase, Bank of America, Barclays, Siemens, Shell, Yahoo!, Microsoft, Cornell University, and the University of Chicago.
“In addition to the raw power of digital currencies, the technology that powers blockchain-based solutions is something that region can’t afford to miss out on,” opined Gardner. “For example, blockchain-based authentication, especially when blended with artificial intelligence technologies, could be a gamechanger in authenticating malaria treatments. Using blockchain verification solutions, African governments could nearly eliminate counterfeit pharmaceuticals, which is a topic our company intends to continue to explore over the coming months and years.”
Biotech Firm Launches Lassa Vaccine Trial in West Africa
Biotech Firm Launches Lassa Vaccine Trial in West Africa
A biotechnology company, INOVIO, says the first participant in Lassa vaccine trial has been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever.
The clinical trial is being done in Ghana, the firm says, adding that INOVIO is focused on bringing to market precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer.
The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa Fever to be conducted in West Africa, where the infection is endemic.
The lead clinical Principal Investigator for LSV-002 is Professor Dr. Kwadwo A. Koram, an expert and specialist in tropical medicines and epidemiologist with more than 20 years of research experience, including malaria vaccines.
INO-4500 was also the first vaccine candidate for Lassa fever to enter human trials, PUNCH Healthwise reports.
Already, the Director-General of the Nigeria Centre for Disease Control, Dr. Chikwe Ihekweazu, has tweeted his commendation.
Said Ihekweazu, “Fantastic news. The urgency of now. A vaccine for Lassa fever. We have worked very hard with WHO, CEPI vaccines, ACEGID, BNITM_de and many others to put this on the global health agenda. We will keep pushing.”
According to a press release by the biotechnology company, INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership that leverages funding from public, private, philanthropic and civil society organisations to support research projects to develop vaccines against emerging infectious diseases.
INOVIO previously received a $56m grant from CEPI in 2018, under which the company is developing vaccine candidates for Lassa Fever and Middle East Respiratory Syndrome (MERS).
“INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phase 2 testing,” the press release stated.
The statement notes that INOVIO’s Phase 1B clinical trial, LSV-002, will enroll approximately 220 adult participants who are 18 – 50 years old, with the primary endpoints of evaluating safety and immunogenicity in an African population.
The dosing regimen involves two vaccinations at zero and 28 days with either 1.0 mg or 2.0 mg dosing levels. In addition to providing valuable insights on the INO-4500 safety and immunogenicity profile, this trial will inform dose selection for subsequent Phase 2 studies in West Africa.
Lassa fever is an animal-borne, acute hemorrhagic viral illness primarily observed in parts of West Africa.
Infection is spread through contact with infected rodents, as well as person-to-person transmission via bodily fluids (primarily in health care settings).
The disease can cause a range of outcomes, including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose and death.
Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, and is responsible for 10 – 16 percent of hospital admissions in the region. The virus is responsible for approximately 5,000 deaths annually.
Because of difficulties in diagnosing Lassa fever, the lack of standardised surveillance assays, and the remote nature of many of the areas in West Africa where outbreaks typically occur, the numbers of reported cases and deaths are very likely significantly lower than the actual numbers of cases and deaths.
Though the majority (about 80 percent) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. The case-fatality among patients hospitalized for Lassa fever is about 15 – 20 percent and, in some epidemics, case-fatality has reached 50 percent in hospitalized patients.
Up until now, there are no licensed vaccines or treatments specifically for Lassa fever.
Stock Market4 weeks ago
Citron Research that Called Jumia Fraud, Ends 20 Years of Short Selling Report After Losing Big on GameStop
News2 weeks ago
Doctors Warn Covid Will Become Endemic and People Need to Learn to Live With it
Bitcoin2 weeks ago
Bitcoin Surges Above $50,000 Per Coin on Tuesday, Sets a New All-Time High
Cryptocurrency3 weeks ago
Why CBN Bans Banks from Facilitating Cryptocurrency Exchanges
Economy3 weeks ago
Petrol Landing Cost Rises to N180, Oil Crosses $60
Economy2 weeks ago
Petrol Subsidy May Hit N11.2bn Per Week
Banking Sector4 weeks ago
Board of Zenith Bank Approves Dividend and Audited Financial Statements for 2020
Banking Sector1 week ago
Banks Turning Female Marketers to Sexual Slaves – Senator